Rafael J. Luque

Prof. Dr. Rafael J. Luque

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AGAdrián González-González
Adrián González-González
EMEsperanza Muñoz-Muela
Esperanza Muñoz-Muela
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
FCFrancisca E. Cara
Francisca E. Cara
MMMaria P. Molina
Maria P. Molina
Sergio Granados-PrincipalSergio Granados-Principal
Sergio Granados-Principal
Purpose: On the basis of the identified stress-independent cellular functions of activating transcription factor 4 (ATF4), we reported enhanced ATF4 levels in MCF10A cells treated with TGFβ1. ATF4 is overexpressed in patients with triple-negative breast cancer (TNBC), but its impact on patient survival and the underlying mechanisms remain unknown. We aimed to determine ATF4 effects on patients with breast cancer survival and TNBC aggressiveness, and the relationships between TGFβ and ATF4. Defining the signaling pathways may help us identify a cell signaling–tailored gene signature. Experimental Design: Patient survival data were determined by Kaplan–Meier analysis. Relationship between TGFβ and ATF4, their effects on aggressiveness (tumor proliferation, metastasis, and stemness), and the underlying pathways were analyzed in three TNBC cell lines and in vivo using patient-derived xenografts (PDX). Results: ATF4 overexpression correlated with TNBC patient survival decrease and a SMAD-dependent crosstalk between ATF4 and TGFβ was identified. ATF4 expression inhibition reduced migration, invasiveness, mammosphere-forming efficiency, proliferation, epithelial–mesenchymal transition, and antiapoptotic and stemness marker levels. In PDX models, ATF4 silencing decreased metastases, tumor growth, and relapse after chemotherapy. ATF4 was shown to be active downstream of SMAD2/3/4 and mTORC2, regulating TGFβ/SMAD and mTOR/RAC1–RHOA pathways independently of stress. We defined an eight-gene signature with prognostic potential, altered in 45% of 2,509 patients with breast cancer. Conclusions: ATF4 may represent a valuable prognostic biomarker and therapeutic target in patients with TNBC, and we identified a cell signaling pathway–based gene signature that may contribute to the development of combinatorial targeted therapies for breast cancer. Clin Cancer Res; 24(22); 5697–709. ©2018 AACR.

4 February 2022 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
ALAntonio Lopez-Beltran
Antonio Lopez-Beltran
ABAna Blanca
Ana Blanca
ALESSIA CIMADAMOREALESSIA CIMADAMORE
ALESSIA CIMADAMORE
RMRodolfo Montironi
Rodolfo Montironi
RLRafael J. Luque
Rafael J. Luque
Liang ChengLiang Cheng
Liang Cheng
: The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological features of 104 HGT1 cases of urothelial carcinoma of the bladder with variant histology present in 34 (37%) were assessed. The endpoint of the study was disease-free survival and cancer-specific survival. Overall, variant histology was identified as a significant predictor of disease-free survival (P = 0.035). The presence of any specific variant histology (squamous, glandular, micropapillary, nested, microcystic, inverted growth, villous-like, basaloid, and lymphoepithelioma-like) was identified as a significant predictor of disease-free survival (P = 0.008) and cancer-specific survival (P = 0.0001) in HGT1 bladder cancer. Therefore, our results support including micropapillary HGT1 urothelial carcinoma within the aggressive high-risk category, as suggested by some recent clinical guidelines, but also favor nested, glandular, and basaloid to be placed in the high-risk category due to their potential of aggressive, life-threatening behavior and their limited response to bacillus Calmette-Guerin therapy. Conversely, the low-risk category would include urothelial carcinomas with squamous, inverted growth, or microcystic morphology, all with limited life-threatening potential and good response to current therapy. A very low-risk category would finally include patients whose tumors present villous-like or lymphoepithelioma-like morphology. In conclusion, our findings support the value of reporting the variant histology as a feature of variable aggressiveness in HGT1 urothelial carcinoma of the bladder.

Verified
Journal Article
Open access
PDF file
NCNuria Cárdenas-Quesada
Nuria Cárdenas-Quesada
Leticia Díaz BeltránLeticia Díaz Beltrán
Leticia Díaz Beltrán
CRCarmen Rosa-Garrido
Carmen Rosa-Garrido
BMBélgica Márquez-Lobo
Bélgica Márquez-Lobo
ASAdela Sabio-González
Adela Sabio-González
PSPedro Sánchez-Rovira
Pedro Sánchez-Rovira
Nowadays, the impact of the tumor-immune microenvironment (TME) in non-small-cell lung cancer (NSCLC) prognosis and treatment response remains unclear. Thus, we evaluated the expression of PD-L1, tumor-infiltrating lymphocytes (TILs), and transforming growth factor beta (TGF-β) in NSCLC to identify differences in TME, detect possible new prognostic factors, and assess their relationship. We retrospectively analyzed 55 samples from patients who underwent NSCLC surgery and had over a 5-year follow-up. PD-L1 expression was determined by immunohistochemistry following standard techniques. The presence of TILs was evaluated at low magnification and classified into two categories, “intense” and “non-intense”. Cytoplasmic TGF-β staining visualization was divided into four categories, and unequivocal nuclear staining in >1% of viable tumor cells was defined as “present” or “absent”. Our aim was to identify differences in disease-free survival (DFS) and overall survival (OS). Tumor stage was the only objective prognostic factor for OS. PD-L1 expression and the presence of TILs had no prognostic impact, neither their combination. There seems to be a lower expression of PD-L1 and a higher expression of TILs in early stages of the disease. Our TGF-β nuclear staining analysis was promising, since it was associated with worse DFS, revealing this protein as a possible prognostic biomarker of recurrence for resectable NSCLC.

31 March 2023
Verified
Other
Open access
AGAdrián González-González
Adrián González-González
EMEsperanza Muñoz-Muela
Esperanza Muñoz-Muela
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
FCFrancisca E. Cara
Francisca E. Cara
MMMaria P. Molina
Maria P. Molina
SGSergio Granados-Principal
Sergio Granados-Principal
Supplementary Figure 2. Target efficiency of ATF4-siRNA, effects of ATF4 knockdown on tumor cell migration, and ATF4 expression in mammospheres.

31 March 2023
Verified
Other
Open access
AGAdrián González-González
Adrián González-González
EMEsperanza Muñoz-Muela
Esperanza Muñoz-Muela
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
FCFrancisca E. Cara
Francisca E. Cara
MMMaria P. Molina
Maria P. Molina
SGSergio Granados-Principal
Sergio Granados-Principal
Supplementary Table S1. Overall survival in low- and high-expression cohorts.

31 March 2023
Verified
Other
Open access
AGAdrián González-González
Adrián González-González
EMEsperanza Muñoz-Muela
Esperanza Muñoz-Muela
Juan Antonio MarchalJuan Antonio Marchal
Juan Antonio Marchal
FCFrancisca E. Cara
Francisca E. Cara
MMMaria P. Molina
Maria P. Molina
SGSergio Granados-Principal
Sergio Granados-Principal
Non-tracked version of the supplementary information document that includes supplementary materials and methods, supplementary references and supplementary figure legends